%0 Journal Article %1 Burstein.2008 %A Burstein, H. J. %A Elias, A. D. %A Rugo, H. S. %A Cobleigh, M. A. %A Wolff, A. C. %A Eisenberg, P. D. %A Lehman, M. %A Adams, B. J. %A Bello, C. L. %A Deprimo, S. E. %A Baum, C. M. %A Miller, K. D. %D 2008 %J J Clin Oncol %K & Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use %N 11 %P 1810-1816 %T Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane %U PM:18347007 %V 26 %X PURPOSE: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Sixty-four patients previously treated with an anthracycline and a taxane received sunitinib 50 mg/d in 6-week cycles (4 weeks on, then 2 weeks off treatment). The primary end point was objective response rate. Plasma samples were obtained for pharmacokinetic and biomarker analysis. RESULTS: Seven patients achieved a partial response (median duration, 19 weeks), giving an overall response rate of 11%. Three additional patients (5%) maintained stable disease for >or= 6 months. Median time to progression and overall survival were 10 and 38 weeks, respectively. Notably, responses occurred in tr

@article{Burstein.2008, abstract = {PURPOSE: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Sixty-four patients previously treated with an anthracycline and a taxane received sunitinib 50 mg/d in 6-week cycles (4 weeks on, then 2 weeks off treatment). The primary end point was objective response rate. Plasma samples were obtained for pharmacokinetic and biomarker analysis. RESULTS: Seven patients achieved a partial response (median duration, 19 weeks), giving an overall response rate of 11%. Three additional patients (5%) maintained stable disease for >or= 6 months. Median time to progression and overall survival were 10 and 38 weeks, respectively. Notably, responses occurred in tr}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Burstein, H. J. and Elias, A. D. and Rugo, H. S. and Cobleigh, M. A. and Wolff, A. C. and Eisenberg, P. D. and Lehman, M. and Adams, B. J. and Bello, C. L. and Deprimo, S. E. and Baum, C. M. and Miller, K. D.}, biburl = {https://www.bibsonomy.org/bibtex/28296f37e81a4e725fc9d421d2b2defe2/kanefendt}, interhash = {0e6cf6ecf94f7aebe05f7c496b165fc6}, intrahash = {8296f37e81a4e725fc9d421d2b2defe2}, journal = {J Clin Oncol}, keywords = {& Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use}, number = 11, pages = {1810-1816}, timestamp = {2010-02-05T11:28:52.000+0100}, title = {Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane}, url = {PM:18347007}, volume = 26, year = 2008 }